6JH0 Stock Chart & Stats
€1.15
--
Market closed
€1.15
--
Day’s Range― - ―
52-Week Range€0.98 - €2.12
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€11.47M
Enterprise Value-€12.77M
Total Cash (Recent Filing)€21.94M
Total Debt (Recent Filing)€2.35M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding9,847,089
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.38Price Target Upside280.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Peer‑reviewed Clinical PublicationA peer‑reviewed JCO publication materially strengthens the scientific credibility of IN8bio's DeltEx platform. This reduces translational risk, supports regulator and KOL engagement, and sustainably improves the company's ability to attract partners and non‑dilutive collaborations over the coming quarters.
Robust Glioblastoma Efficacy SignalA large PFS improvement in newly diagnosed glioblastoma is a durable, disease‑level competitive advantage. Strong clinical efficacy in an underserved indication can open accelerated regulatory pathways, justify pivotal trials, and make the asset attractive for licensing or strategic partnerships.
Improving Cash Position And Low LeverageA strengthened cash balance, materially reduced operating burn versus prior years, and low leverage provide a more durable runway and financial flexibility. This lowers near‑term financing urgency and preserves optionality for executing clinical milestones and partnering discussions.
Bears Say
No Revenue And Persistent LossesAs a clinical‑stage biotech with no commercial revenue, IN8bio remains cash‑flow negative and dependent on external financing. Continued operating losses mean the company cannot self‑fund development, sustaining dilution risk and constraining long‑term strategic autonomy absent partnerships.
Eroding Equity BaseA materially shrinking equity base reduces the balance‑sheet cushion against trial setbacks and limits non‑dilutive funding options. This structural deterioration increases the probability of future dilutive equity raises or unfavorable financing terms, altering capital allocation and governance dynamics.
Binary Clinical/regulatory RiskIN8bio's long‑term viability hinges on successful late‑stage trial outcomes and regulatory approvals. As an early‑stage developer with binary clinical milestones, the company faces durable execution risk, long timelines, and potential need for strategic partners to commercialize therapies.
IN8bio News
6JH0 FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was €0.97 and its highest was €2.12 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is €11.47M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 24 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on May 07, 2026. The company reported -€0.228 earnings per share for the quarter, beating the consensus estimate of -€0.541 by €0.314.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.3.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 9,847,089 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -€0.228 in its last earnings report, beating expectations of -€0.541. Following the earnings report the stock price went down -0.827%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in DE:6JH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
In8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
6JH0 Stock 12 Month Forecast
Average Price Target
€4.38
▲(280.78% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―
Options Prices
Currently, No data available
---